Stentys sirolimus-eluting stent confirms best-in-class performance at three years


Stentys has announced that the long-term performance of the siromilus-eluting Self-Apposing stent has been confirmed by three-year follow-up imaging data from the Stentys arm of the APPOSITION IV clinical. The data was presented by Robert-Jan van Geuns from Erasmus Medical Center in Rotterdam at the Transcatheter Cardiovascular Therapeutics Conference.

The data were obtained by Quantitative Coronary Angiography (QCA) and Optical Coherence Tomography (OCT) from a group of patients that were examined three years post-treatment for ST-elevation Myocardial Infarction with the Stentys stent. The in-stent Late Lumen Loss was 0.08mm (±0.43), while the rate of well-apposed struts was 99.3% and the rate of strut covered by tissue was 99.7%.

Van Geuns says “These images reinforce our confidence that the STENTYS Sirolimus-eluting stent performs very well, not only in the short-term, as previously demonstrated, but also at a much later time point.”

CEO and co-founder of Stentys, Gonzague Issenmann, states “We expect that these exciting long-term results for our Sirolimus-eluting Self-Apposing stent will further drive adoption as cardiologists recognise the potential to optimally treat their patients without the risk of severe malapposition observed with conventional stents.